Working Note: Nan Shan Life Insurance

Knowledge Snapshot

This file is issuer coverage memory for objective context. Detailed figures are stored primarily in data/nan_shan_life_insurance_key_metrics_20260514.json.

Last updated: 2026-08-28

Issuer Overview

• Nan Shan Life Insurance Company, Ltd. is a major Taiwan life insurer founded in July 1963.
• Official company sources reviewed for the current report describe more than 4,000 employees, more than 30,000 agents, more than 6.7 million policyholders, more than 11.7 million in-force policies, 25 branches, and 291 agency offices.
• The company should be analysed as a life insurer with long-duration policyholder liabilities and a large domestic and offshore investment portfolio.
• Official company homepage disclosures for 2024 showed paid-in capital of NT$147bn, total assets of about NT$5.6tn, and shareholders' equity of NT$356.3bn, with top-three industry positioning for total assets and shareholders' equity.

Core Credit View

• The credit profile combines a large Taiwan insurance franchise, high persistency, investment-grade ratings, and demonstrated capital-market access with material FX, ALM, insurance-liability, and subordinated-capital risks.
• The central constraint is the structure identified by Fitch: US dollar assets exceed US dollar liabilities and are used to back Taiwan-dollar-denominated obligations. Sustained Taiwan-dollar appreciation can pressure earnings, capital, hedge costs, and ratings.
• 2025 capital reinforcement through USD Tier 2 issuance helped stabilise the rating view, but it did not remove the underlying currency-mismatch and ALM issues.
• The H1 2026 official consolidated financial statements, disclosed on 2026-08-26, strengthened the positive direction seen in Q1: H1 net profit was NT$30.9bn, equity rose to NT$563.0bn, and issued-contract CSM rose to NT$392.8bn. The report confirms compliance with applicable capital-adequacy and net-worth requirements but does not disclose numerical ICS headroom, detailed hedge costs, ALM, policyholder-behaviour, claims or product-profitability data; it therefore does not establish that FX and capital constraints have been resolved.

Business and Franchise View

• Nan Shan Life has a long operating history, broad agency distribution, a large policyholder base, and top-tier scale in Taiwan's life insurance market.
• Product scope includes traditional life, health and medical, accident, annuity, investment-linked, foreign-currency, and related insurance products.
• FYP growth is credit-supportive only if product profitability, guarantees, claims, capital consumption, and hedging burden remain manageable. Product growth should not be treated as unconditional credit improvement.
• Nan Shan General Insurance is a wholly owned non-life subsidiary, but current memory does not contain enough standalone non-life financial information to treat it as a major credit driver.

Capital Structure and Structural Points

• Official rating material showed S&P A- / Stable, Taiwan Ratings twAA+ / Stable, and Fitch A- / AA(twn) / Stable as of November 2025.
• Fitch's 2025 rating action affirmed the IFS at A-, Long-Term IDR at BBB+, and USD subordinated dated capital bonds issued by Nanshan Life Pte. Ltd. at BBB.
• Nanshan Life Pte. Ltd. is a Singapore-incorporated wholly owned subsidiary of Nan Shan Life. Its USD Tier 2 subordinated dated capital bonds are guaranteed by Nan Shan Life, but the instruments remain subordinated capital securities rather than senior debt.
• The 2025 USD Tier 2 series totalled USD653mn after an initial USD395mn issue and a USD258mn tap, with a 5.875% coupon and 2041 maturity according to the transaction source.

Liquidity and Funding View

• Nan Shan Life's liquidity and funding analysis should focus on insurance liabilities, investment-asset liquidity, surrender behaviour, hedge costs, cash and cash equivalents, debt maturities, and regulatory capital.
• The investment portfolio is large and dominated by offshore fixed-income assets. Detailed figures are retained in the JSON data file rather than repeated here.
• Monthly self-reported earnings and FYP data are useful for direction, but they are unaudited and can be volatile for insurers.
• The official H1 2026 financial statements should be used ahead of isolated monthly results when assessing the 2026 direction. They confirm positive H1 earnings and higher reported equity under the IFRS 17 / IFRS 9 basis, but cash fell to NT$120.0bn and operating cash flow was negative; portfolio liquidity, surrender behaviour, collateral and hedge needs remain necessary to interpret those cash movements.

Credit Strengths

• Large and established Taiwan life-insurance franchise.
• Broad agency network and policyholder base.
• High persistency in the available 2025 data.
• Investment-grade rating recognition from major rating agencies.
• Demonstrated access to international capital markets through the 2025 USD Tier 2 issuance.

Credit Weaknesses

• Material FX and ALM exposure from offshore assets backing Taiwan-dollar obligations.
• Earnings and capital sensitivity to Taiwan-dollar appreciation, hedge costs, market valuations, and unrealized losses.
• Long-duration insurance liabilities with assumption risk around guarantees, surrenders, claims, and liability adequacy.
• Limited current visibility on audited FY2025 detail, ALM gap, guaranteed rates, claims ratios, and detailed hedging profile.
• Tier 2 investors face subordination and capital-instrument risks that are separate from issuer credit.

Rating Watchpoints

• Fitch's removal of Rating Watch Negative in November 2025 indicates stabilisation under its base case, not elimination of FX risk.
• Rating analysis must keep IFS, IDR, national-scale ratings, domestic subordinated ratings, and USD Tier 2 ratings separate.
• Rating pressure could re-emerge if FX losses deplete reserves and capital buffers, capital strength weakens, or profitability remains weak for a prolonged period.

Recurring Analytical Cautions

• Do not rely on company size alone as a credit conclusion.
• Do not infer that a guaranteed Tier 2 security has senior-debt protection.
• Do not use unaudited monthly results as a substitute for annual or interim financial statements.
• Do not assert detailed S&P or Taiwan Ratings rationale until the original reports are obtained.

Reliable Core Sources

• Nan Shan Life official history, homepage, product page, annual financial information, interim consolidated financial statements, monthly financial information, 2024 annual report, and official credit ratings material.
• Nan Shan Life H1 2026 consolidated financial statements and independent auditors' report, disclosed 2026-08-26, for official interim earnings, balance-sheet, cash-flow and CSM confirmation under the IFRS 17 / IFRS 9 basis.
• Fitch 2025 rating action detail as republished by Reuters / TradingView, pending direct confirmation from the original Fitch page.
• Allen & Gledhill transaction note for the 2025 USD Tier 2 issue and tap.
• data/nan_shan_life_insurance_key_metrics_20260514.json for structured financial, operating, capital, rating, and Tier 2 data.
• data/nan_shan_life_insurance_q1_2026_results_20260623.json and data/nan_shan_life_insurance_q2_1h_2026_results_20260828.json for structured official 2026 interim financial data and credit-read-through tags.

Issuer Notes

This file is issuer coverage memory for research and writing judgment. It is not a work log.

Last updated: 2026-08-28

Ongoing Follow-Up Items

• Track USD/TWD, Taiwan-dollar appreciation pressure, FX valuation reserve, hedging costs, and the Fitch sensitivity around sustained Taiwan-dollar appreciation from the end-3Q25 level.
• Recheck RBC ratio, Fitch Prism score, total equity, total equity plus FX valuation reserve, and the impact of Taiwan's TW-ICS / IFRS 17 capital transition.
• After H1 2026 official financial statements, track whether positive earnings, increased reported equity and higher CSM persist through Q3 despite market, FX, hedge and insurance-liability movements; obtain the numerical ICS ratio, net-worth ratio and capital buffer rather than relying on the disclosed compliance statement.
• Reconcile the H1 fall in cash and negative operating cash flow with investment-portfolio liquidity, collateral and hedging needs, policyholder cash flows and surrender behaviour before drawing a liquidity conclusion.
• Monitor overseas fixed-income portfolio size, credit quality, duration, unrealized gains/losses, hedge costs, and liquidity under surrender or market stress.
• Monitor insurance contract liabilities, guarantee rates, liability adequacy, lapse / surrender rates, and 13-month and 25-month persistency.
• Track health, accident, medical, and long-term care claims trends, pricing power, repricing lag, and reinsurance protection.

Unresolved Issues and Items to Check Next Time

• Obtain the full audited 2025 annual financial statements and detailed notes. The 2025 Annual Financial Information is useful but should not be treated as a full audited annual report.
• Obtain the full S&P Global Ratings and Taiwan Ratings reports dated 2025-11-26, if accessible, before relying on their detailed rationale or triggers.
• Confirm the original Fitch rating action page or full text for the 2025-11-14 affirmation and Rating Watch Negative removal; current memory relies on a Reuters / TradingView republication for Fitch detail.
• Obtain the USD Tier 2 Offering Circular and trust deed, including coupon deferral, write-down or conversion language, regulatory call, tax call, redemption approval, ranking of the issuer guarantee, and fund-transfer mechanics between Nanshan Life Pte. Ltd. and Nan Shan Life.
• Reconcile the 2025 FYP difference between the NT$82.2bn figure in the Annual Financial Information composition table and the NT$92.997bn cumulative figure in the December 2025 monthly self-reported data.
• Confirm the currency split of insurance liabilities, asset-liability duration gap, guarantee rates, product-level new business value, claims ratios, lapse assumptions, morbidity assumptions, and reinsurance program.
• Confirm CSM movement, new-business CSM, insurance-service-result drivers, hedging cost and FX valuation reserve movements under the IFRS 17 / IFRS 9 basis when company materials provide more detail. The H1 report confirms higher CSM but does not provide sufficient information to attribute it to durable new-business economics or reduced financial risk.
• Obtain market price, spread, yield, OAS, same-tenor comparables, and peer insurance Tier 2 comparables before making any relative-value judgment.

Analytical Cautions

• Analyse Nan Shan Life as a life insurer with long-duration policyholder liabilities and a very large investment portfolio, not as a bank or general corporate issuer.
• Keep franchise strength separate from market-risk resilience. Large scale, high persistency, and a broad agency network do not eliminate FX, ALM, hedge-cost, unrealized-loss, surrender, claims, or regulatory-capital risk.
• Treat FYP growth as conditionally positive only after checking product mix, margins, capital consumption, guarantees, claims, and hedging burden.
• Do not infer that offshore fixed-income assets are credit-neutral because they are bonds; their currency, duration, accounting classification, liquidity, hedge cost, and credit-spread sensitivity matter.
• Do not transfer the issuer credit view directly to Tier 2 securities. Subordination, capital character, coupon restrictions, redemption approval, regulatory loss absorption, and guarantee ranking must be assessed separately.
• Distinguish IFS, IDR, national-scale ratings, domestic subordinated-debt ratings, and USD Tier 2 ratings in all report language.

Report Wording Cautions

• Avoid saying or implying that the USD Tier 2 guarantee is equivalent to senior unsecured protection.
• Avoid stating that Nan Shan Life has resolved FX risk. The correct framing is that near-term rating pressure has stabilised after capital reinforcement, while currency mismatch remains a key constraint.
• Avoid describing S&P or Taiwan Ratings triggers unless the original rating reports have been obtained.
• Avoid definitive peer-superiority claims versus Cathay Life, Fubon Life, KGI Life, Taiwan Life, or other Taiwanese insurers without a consistent peer dataset.
• Do not use the March 2026 monthly net loss alone as evidence of credit deterioration; monthly insurer earnings can be volatile and should be checked against quarterly, semi-annual, and annual materials.
• Do not treat the positive H1 2026 result, higher CSM or improved reported equity as evidence that FX or capital risk has been resolved. The correct framing is that profitability and capital presentation improved while regulatory-capital, FX, ALM, liquidity, policyholder-behaviour and product-profitability checks remain open.

Follow-Up on Management Strategy, Investment Plans, and Financial Policy

• Confirm whether the company is materially increasing US dollar-denominated policy sales or Taiwan-dollar assets to reduce currency mismatch, and whether this improves economic ALM rather than only new-business mix.
• Check whether capital reinforcement after the USD653mn Tier 2 issuance is recurring, opportunistic, or tied to regulatory-capital transition.
• Monitor capital-management policy, dividend posture, product strategy, hedging approach, and potential changes in risky-asset allocation.
• Monitor whether the IFRS 17 / IFRS 9 presentation changes reported earnings volatility, capital communication, and management's product or asset-allocation incentives.

Items to Check for Ratings and Bond Investors

• Reconfirm Fitch IFS, Long-Term IDR, national ratings, domestic subordinated-debt ratings, and USD Tier 2 rating from original rating-agency sources whenever possible.
• Check RBC, Prism, FX reserve, unrealized gains/losses, capital buffers, and downgrade sensitivities at each update.
• For individual bonds, review issuer, guarantor, ranking, coupon suspension, loss absorption, first call date, step-up, regulatory call, tax call, redemption approval, governing law, and liquidity before making any investment view.